Related references
Note: Only part of the references are listed.Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology
Marie-Victoire Guillot-Sestier et al.
NEURON (2015)
IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior
Paramita Chakrabarty et al.
NEURON (2015)
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation
Ulrike Traeger et al.
BRAIN (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
Massimo Filippi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
Manoj Kumar Mishra et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
The Role of the Immune System in Huntington's Disease
Gisa Ellrichmann et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease
Han-Yun Hsiao et al.
HUMAN MOLECULAR GENETICS (2013)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Wolfgang Brueck et al.
ACTA NEUROPATHOLOGICA (2012)
NF-κB, the first quarter-century: remarkable progress and outstanding questions
Matthew S. Hayden et al.
GENES & DEVELOPMENT (2012)
Mutant huntingtin impairs immune cell migration in Huntington disease
Wanda Kwan et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease
Wanda Kwan et al.
JOURNAL OF NEUROSCIENCE (2012)
Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease
Jill Bouchard et al.
JOURNAL OF NEUROSCIENCE (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
Ulf Schulze-Topphoff et al.
PLOS ONE (2012)
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Daniel Zwilling et al.
CELL (2011)
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's Disease: A multimodal imaging study
Marios Politis et al.
HUMAN BRAIN MAPPING (2011)
Insight into the mechanism of laquinimod action
W. Brueck et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Gisa Ellrichmann et al.
PLOS ONE (2011)
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: In-vitro high-throughput gene expression study
M. Gurevich et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
A Futility Study of Minocycline in Huntington's Disease
Heidi Schwarz et al.
MOVEMENT DISORDERS (2010)
Oral laquinimod therapy in relapsing multiple sclerosis
Jana Preiningerova
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
Maria Bjorkqvist et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration
Karine Palin et al.
NEUROBIOLOGY OF DISEASE (2008)
Microglial activation in presymptomatic Huntington's disease gene carriers
Yen F. Tai et al.
BRAIN (2007)
The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I:C)
Colin Cunningham et al.
BRAIN BEHAVIOR AND IMMUNITY (2007)
Systemic infections and inflammation affect chronic neurodegeneration
V. Hugh Perry et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates
Annette Dalrymple et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Microglial activation correlates with severity in Huntington disease - A clinical and PET study
N. Pavese et al.
NEUROLOGY (2006)
Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling
Carl Johan Sennbro et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)
Activation of the IκB kinase complex and nuclear factor-κB contributes to mutant Huntingtin neurotoxicity
A Khoshnan et al.
JOURNAL OF NEUROSCIENCE (2004)
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
HS Yang et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Minocycline in Huntington's disease: A pilot study
M Thomas et al.
MOVEMENT DISORDERS (2004)
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephomyelitis
C Brunmark et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
LP Zou et al.
NEUROPHARMACOLOGY (2002)
Early and progressive accumulation of reactive microglia in the Huntington disease brain
E Sapp et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2001)
Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice
DX Chen et al.
NATURE MEDICINE (2000)
Share Paper
